Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3772 results
ArmaGen, Shire to develop AGT-182 for treatment of hunter syndrome
ArmaGen, a privately held biotechnology company, has announced that it has entered into a worldwide licensing and collaboration agreement with Shire plc to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter syndrome.
Drug Research > Drug Discovery & Development > News
Bristol-Myers enters into immuno-oncology collaboration with Ono Pharmaceutical
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
Drug Research > Drug Discovery & Development > News
Cynapsus Therapeutics commences Phase II clinical trials in US
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson's disease, has announced that following communication from the United States Food and Drug Administration, Phase II clinical studies for APL-130277 will commence immediately.
Drug Research > Drug Discovery & Development > News
MYOS enters into R&D agreement with Cloud Pharmaceuticals
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research and development agreement with Cloud Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Isis Pharmaceuticals initiates Phase 2 study of ISIS-APO(a) in patients with high Lp(a)
Isis Pharmaceuticals announced the initiation of a Phase 2 study evaluating ISIS-APO(a) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
Drug Research > Drug Discovery & Development > News
Lilly, Immunocore to jointly discover and develop new cancer therapies
By PBR Staff Writer
US-based Eli Lilly and Company has entered into a co-discovery and co-development collaboration with British biotechnology firm Immunocore to research and potentially develop new T cell-based cancer therapies.
Drug Research > Drug Discovery & Development > News
BioLineRx reports results from Phase 1/2 study for celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
ChromaDex begins first human clinical study to confirm ChromaDex's NIAGEN Nicotinamide Riboside will increase NAD+
ChromaDex, an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN, the first and only commercially available form of nicotinamide riboside (NR).
Drug Research > Drug Discovery & Development > News
Roche's Phase III trial of melanoma combination therapy meets primary endpoint
By PBR Staff Writer
Roche has released positive results from the Phase III coBRIM trial of an investigational MEK inhibitor cobimetinib, used in combination with its BRAF inhibitor Zelboraf, to treat patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
Drug Research > Drug Discovery & Development > News
Helix BioPharma announces completion of private placement
BioPharma, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, has announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Drug Research > Drug Discovery & Development > News
Ipsen, Galderma become exclusive partners for development and marketing of neurotoxins
Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, has announced that they have significantly expanded the scope of their neurotoxin partnership.
Drug Research > Drug Discovery & Development > News
HD Biosciences, Marshall University enter drug discovery co-development deal
By PBR Staff Writer
HD Biosciences, a China-based biology-focused preclinical drug discovery contract research organization (CRO), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine have announced a new partnership to co-develop potential anti-cancer drugs for unmet healthcare needs in both international and Chinese markets.
Drug Research > Drug Discovery & Development > News
Threshold starts dosing in Phase I/II trial of myeloma combination drug TH-302/Bortezomib
By PBR Staff Writer
Threshold Pharmaceuticals has initiated dosing patients in the final stage of an ongoing Phase I/II trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone (TBorD) for the treatment of relapsed/refractory multiple myeloma.
Drug Research > Drug Discovery & Development > News
Compugen discloses achievement of milestone in cancer immunotherapy collaboration with Bayer
Compugen has disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer).
Drug Research > Drug Discovery & Development > News
BioMarin gets Health Canada approval of VIMIZIM to treat morquio a syndrome
BioMarin Pharmaceutical has announced that Health Canada has approved VIMIZIM(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Drug Research > Drug Discovery & Development > News
61-75 of 3772 results